Previous Study: TRIO036
Next Study: TRIO033

Studies & Results

TRIO035

A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (MT-5111-001)

View FDA Study

For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org